CDC25 phosphatases in cancer cells: key players? Good targets?

被引:577
作者
Boutros, Rose
Lobjois, Valerie
Ducommun, Bernard
机构
[1] Univ Toulouse, Inst Explorat Fonct Genomes, F-31062 Toulouse, France
[2] CHU Purpan, UA4124, F-31059 Toulouse, France
关键词
CYCLE-ACTIVATING PHOSPHATASES; DUAL-SPECIFICITY PHOSPHATASE; HUMAN COLORECTAL-CARCINOMA; NON-HODGKINS-LYMPHOMAS; HUMAN BREAST-CANCER; S-PHASE CHECKPOINT; POLO-LIKE KINASE; DNA-DAMAGE; BETA-TRCP; FISSION YEAST;
D O I
10.1038/nrc2169
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cell division cycle 25 ( CDC25) phosphatases regulate key transitions between cell cycle phases during normal cell division, and in the event of DNA damage they are key targets of the checkpoint machinery that ensures genetic stability. Taking only this into consideration, it is not surprising that CDC25 overexpression has been reported in a significant number of human cancers. However, in light of the significant body of evidence detailing the stringent complexity with which CDC25 activities are regulated, the significance of CDC25 overexpression in a subset of cancers and its association with poor prognosis are proving difficult to assess. We will focus on the roles of CDC25 phosphatases in both normal and abnormal cell proliferation, provide a critical assessment of the current data on CDC25 overexpression in cancer, and discuss both current and future therapeutic strategies for targeting CDC25 activity in cancer treatment.
引用
收藏
页码:495 / 507
页数:13
相关论文
共 164 条
  • [21] Genotoxic-activated G2-M checkpoint exit is dependent on CDC25B phosphatase expression
    Bugler, Beatrix
    Quaranta, Muriel
    Aressy, Bernadette
    Brezak, Marie-Christine
    Prevost, Gregoire
    Ducommun, Bernard
    [J]. MOLECULAR CANCER THERAPEUTICS, 2006, 5 (06) : 1446 - 1451
  • [22] Initiation of a G2/M checkpoint after ultraviolet radiation requires p38 kinase
    Bulavin, DV
    Higashimoto, Y
    Popoff, IJ
    Gaarde, WA
    Basrur, V
    Potapova, O
    Appella, E
    Fornace, AJ
    [J]. NATURE, 2001, 411 (6833) : 102 - 107
  • [23] Bureik M, 2000, INT J ONCOL, V17, P1251
  • [24] Cdc25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysis
    Busino, L
    Chiesa, M
    Draetta, GF
    Donzelli, M
    [J]. ONCOGENE, 2004, 23 (11) : 2050 - 2056
  • [25] Degradation of Cdc25A by β-TrCP during S phase and in response to DNA damage
    Busino, L
    Donzelli, M
    Chiesa, M
    Guardavaccaro, D
    Ganoth, D
    Dorrello, NV
    Hershko, A
    Pagano, M
    Draetta, GF
    [J]. NATURE, 2003, 426 (6962) : 87 - 91
  • [26] Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia
    Byrd, John C.
    Lin, Thomas S.
    Dalton, James T.
    Wu, Di
    Phelps, Mitch A.
    Fischer, Beth
    Moran, Mollie
    Blum, Kristie A.
    Rovin, Brad
    Brooker-McEldowney, Michelle
    Broering, Sarah
    Schaaf, Larry J.
    Johnson, Amy J.
    Lucas, David M.
    Heerema, Nyla A.
    Lozanski, Gerard
    Young, Donn C.
    Suarez, Jose-Ramon
    Colevas, A. Dimitrios
    Grever, Michael R.
    [J]. BLOOD, 2007, 109 (02) : 399 - 404
  • [27] Role of the Cdc25A phosphatase in human breast cancer
    Cangi, MG
    Cukor, B
    Soung, P
    Signoretti, S
    Moreira, G
    Ranashinge, M
    Cady, B
    Pagano, M
    Loda, M
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2000, 106 (06) : 753 - 761
  • [28] Halenaquinone and xestoquinone derivatives, inhibitors of Cdc25B phosphatase from a Xestospongia sp.
    Cao, SG
    Foster, C
    Brisson, M
    Lazo, JS
    Kingston, DGI
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2005, 13 (04) : 999 - 1003
  • [29] CDC25B phosphorylation by Aurora-A occurs at the G2/M transition and is inhibited by DNA damage
    Cazales, M
    Schmitt, E
    Montembault, E
    Dozier, C
    Prigent, C
    Ducommun, B
    [J]. CELL CYCLE, 2005, 4 (09) : 1233 - 1238
  • [30] Pharmacologic inhibition of CDC25 phosphatases impairs interphase microtubule dynamics and mitotic spindle assembly
    Cazales, Martine
    Boutros, Rose
    Brezak, Marie-Christine
    Chaumeron, Sophie
    Prevost, Gregoire
    Ducommun, Bernard
    [J]. MOLECULAR CANCER THERAPEUTICS, 2007, 6 (01) : 318 - 325